STOCK TITAN
  1. Home
  2. News
  3. ABBV

ABBVIE INC. - ABBV STOCK NEWS

Welcome to our dedicated page for ABBVIE news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on ABBVIE stock.

AbbVie Inc. (NYSE: ABBV), headquartered in North Chicago, Illinois, is a leading pharmaceutical company ranked 6th on the list of largest biomedical companies by revenue. Known for their commitment to delivering innovative medicines, AbbVie focuses on several key therapeutic areas including immunology, oncology, neuroscience, and eye care. Their portfolio also includes products and services in aesthetics through Allergan Aesthetics, a company they acquired in 2020.

AbbVie’s flagship product, Humira (adalimumab), generated $21 billion in revenue in 2022, accounting for 37% of the company's total revenues. Humira is approved for the treatment of various autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. Beyond Humira, AbbVie has developed other notable immunology drugs, including Skyrizi and Rinvoq, which have shown strong market performance.

In the oncology sector, AbbVie markets Imbruvica and Venclexta, which are critical in treating hematological malignancies. The acquisition of Allergan also brought in new products in aesthetics, including Botox, which is not only a cosmetic treatment but also used therapeutically for various conditions.

AbbVie's research and development efforts are robust, with numerous clinical trials ongoing across its therapeutic areas. Recent achievements include positive topline results from the LEVEL UP study, which demonstrated the efficacy of Rinvoq in treating atopic dermatitis. Financially, AbbVie continues to perform well, reporting first-quarter 2024 revenues of $12.310 billion, a 0.7% increase from the previous year.

Strategic partnerships are also a cornerstone of AbbVie’s growth strategy. Recent collaborations include an agreement with Gilgamesh Pharmaceuticals to develop neuroplastogens for psychiatric disorders and a partnership with Landos Biopharma to enhance their immunology portfolio.

AbbVie remains focused on its mission to address serious health issues and improve patient outcomes globally, leveraging its comprehensive pipeline and innovative solutions in biomedical research.

News

Allergan Aesthetics Releases "Decoding the Future of Aesthetic Individuality" Exploring the Power of Self-Expression

Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, released the 'Decoding the Future of Aesthetic Individuality' report, focusing on understanding the evolving consumer mix and their aesthetic needs. The report highlights the importance of individuality in aesthetics and the need for personalized approaches to consultation and treatment. It also emphasizes the role of social media in shaping beauty standards and the impact of individuality on defining beauty. The research includes insights from leading global experts and extensive research across consumer and business media, global social listening data, and market and industry reports from multiple geographies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
-
News

Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024

Rhea-AI Summary
Allergan Aesthetics, a global leader in aesthetics, will be showcasing its commitment to Individuality, Innovation, and Integrity at the IMCAS World Congress 2024. The event will feature a symposium, live injection session, Meet the Expert presentations, and an interactive exhibition booth, all centered around the theme 'True Originals'. The company will also present new clinical data to support its evolving aesthetics portfolio. The AMI symposium will focus on the impact of delivering individualized aesthetic results through real-world examples, with a live injection session from the Allergan Center of Excellence in Italy. The event will also mark the preview of the 'Moving the Needle on Ethics' book, a compilation of thought-provoking pieces on ethical topics associated with aesthetics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
News

Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.

Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, has announced the results of a consumer survey for its loyalty rewards program, Allē, showing a ninety-two percent satisfaction rate among members treated in the past twelve months. Allē aims to educate consumers and solidify its position as the leading aesthetics loyalty rewards program in the country.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none
News

AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

Rhea-AI Summary
AbbVie (ABBV) launches PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson's disease. The subcutaneous 24-hour infusion of levodopa-based therapy demonstrated sustained improvements in 'Off' time, 'On' time without dyskinesia, and morning akinesia. Parkinson's disease affects approximately 6.1 million people globally and is expected to double by 2040. PRODUODOPA provides continuous delivery of levodopa, extending the period when symptoms are well-controlled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
News

Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3

Rhea-AI Summary
AbbVie (ABBV) announces Phase 2 results for lutikizumab in adults with hidradenitis suppurativa, showing higher response rates in HS Clinical Response (HiSCR 50) at week 16 than those treated with placebo. The study also revealed higher response rates in skin pain NRS30 at week 16 among patients with baseline NRS≥3. The program reflects AbbVie's leadership in immunology and a history of investigating new options for patients with HS, addressing a significant unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
clinical trial
-
News

AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies

Rhea-AI Summary
AbbVie (NYSE: ABBV) and Umoja Biopharma announced two exclusive option and license agreements to develop in-situ generated CAR-T cell therapy candidates in oncology using Umoja's proprietary VivoVecTM platform. The collaboration combines AbbVie's expertise in oncology with Umoja's gene delivery platform to advance next-generation in-situ CAR-T therapies. Umoja received upfront payments and an equity investment from AbbVie, with the potential to earn up to $1.44B in aggregate for option exercise fees, development and regulatory milestones, and additional sales-based milestones and tiered royalties on worldwide net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
News

AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call

Rhea-AI Summary
AbbVie (NYSE: ABBV) to announce full-year and fourth-quarter 2023 financial results on February 2, 2024, before market opens. Live webcast of earnings conference call at 8 a.m. CT accessible through AbbVie's Investor Relations website at investors.abbvie.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
conferences earnings
-
News

AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
AbbVie (NYSE: ABBV) to participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Key executives to present at the event, with a live audio webcast accessible through AbbVie's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
-
News

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

Rhea-AI Summary
Genmab A/S (GMAB) and AbbVie (ABBV) reported new data from the phase 1/2 EPCORE™ NHL-1 clinical trial for epcoritamab, showing an 82% overall response rate, 63% complete response rate, and 67% minimal residual disease negativity in patients with relapsed/refractory follicular lymphoma. The study presented at the 65th ASH Annual Meeting and Exposition also highlighted an optimized dosing schedule for FL patients, reducing the risk and severity of cytokine release syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Rhea-AI Summary
AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates. The median duration of response was not reached. The FDA granted Breakthrough Therapy Designation to epcoritamab for the treatment of adult patients with R/R FL after two or more therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of ABBVIE (ABBV)?

The current stock price of ABBVIE (ABBV) is $166.28 as of November 18, 2024.

What is the market cap of ABBVIE (ABBV)?

The market cap of ABBVIE (ABBV) is approximately 293.7B.

What is AbbVie's primary product?

AbbVie's primary product is Humira (adalimumab), which generated $21 billion in revenue in 2022.

What are the key therapeutic areas AbbVie focuses on?

AbbVie focuses on immunology, oncology, neuroscience, and eye care.

What significant achievement did AbbVie report in their research efforts?

AbbVie reported positive results from the LEVEL UP study, demonstrating the efficacy of Rinvoq in treating atopic dermatitis.

Who are AbbVie's notable partners?

AbbVie has strategic partnerships with companies like Gilgamesh Pharmaceuticals and Landos Biopharma.

What are some of AbbVie's key oncology products?

Key oncology products include Imbruvica and Venclexta.

How did AbbVie perform financially in the first quarter of 2024?

AbbVie reported first-quarter 2024 revenues of $12.310 billion, a 0.7% increase from the previous year.

What products did AbbVie acquire through Allergan?

Through Allergan, AbbVie acquired products in aesthetics, including Botox.

What is AbbVie's mission?

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues and improve patients' lives globally.

What percentage of revenue did Humira contribute in 2022?

Humira contributed 37% of AbbVie's total revenues in 2022.

Where is AbbVie headquartered?

AbbVie is headquartered in North Chicago, Illinois.

Stock ABBV logo
ABBVIE INC.

NYSE:ABBV

ABBV Rankings

#28 Ranked by Market Cap
#762 Ranked by Dividends

ABBV Stock Data

293.72B
1.77B
0.1%
73.43%
1.03%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NORTH CHICAGO